Stephen Naylor
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2018First federal award
$6.5MFederal grants as PI8 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
8 awards · $6.5M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Sep 17, 2026 | NIH | SBIR Phase II KYC, an inhibitor of sickle cell disease's vicious cycle in vaso-occlusive crisis and pain | $967K | ReNeuroGen LLC |
| Sep 22, 2025 | NIH | SBIR Phase II KYC, an inhibitor of sickle cell disease's vicious cycle in vaso-occlusive crisis and pain | $1.0M | ReNeuroGen LLC |
| Apr 17, 2025 | NIH | SBIR Phase II Development of a systems pharmacology agent for treatment of bronchopulmonary dysplasia | $50K | ReNeuroGen LLC |
| Jun 14, 2024 | NIH | SBIR Phase II Development of a systems pharmacology agent for treatment of bronchopulmonary dysplasia | $1.9M | ReNeuroGen LLC |
| Jun 15, 2023 | NIH | SBIR Phase II Development of a systems pharmacology agent for treatment of bronchopulmonary dysplasia | $1.0M | ReNeuroGen LLC |
| Jun 13, 2023 | NIH | SBIR Phase II Development of a systems pharmacology agent for treatment of bronchopulmonary dysplasia | $1.0M | ReNeuroGen LLC |
| Aug 4, 2018 | NIH | SBIR Phase I KYC Reduces Vasculopathy in Sickle Cell Disease | $274K | ReNeuroGen LLC |
| Jun 22, 2018 | NIH | SBIR Phase I A Novel Myeloperoxidase Inhibitor for Treating Multiple Sclerosis | $286K | ReNeuroGen LLC |
Peer ranks
Federal funding#160
Awards as PI#190
Patents#273
Companies
- ReNeuroGen LLCLinked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.